In this episode, Part 1 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data from the ACTT-1 trial comparing remdesivir vs placebo for severe COVID-19 treatment. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.Presenter:Vikramjit Mukherjee, MDDirector, Medical Intensive Care UnitBellevue HospitalAssistant ProfessorDivision of Pulmonary, Critical Care, and Sleep MedicineNYU School of MedicineNew York, New YorkContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related